EPS growth is an important number as it indicates the future prospects of Actinium Pharmaceuticals Delaware. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but EPS has been 66.67% over the last twelve months. EPS growth is a vital measure of execution of the strategy for Actinium Pharmaceuticals Delaware since it indicates how well the business is allocating resources to benefit shareholders.
Actinium Pharmaceuticals Delaware trades as part of the biotechnology industry and is in the healthcare sector. The company CEO is Sandesh Seth. Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company’s product portfolio includes Iomab-B and Actimab-A.
Previous Intraday Performance:
The ATNM shares had a previous change of 2.67% which opened at 0.58 and closed at 0.58. It moved to an intraday high of 0.59 and a low of 0.56.
PR Newswire: Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
Historical Performance:
Over the last five trading days, ATNM shares returned 30.48% and in the past 30 trading days it returned -18.72%. Over three months, it changed -9.30%. In one year it has changed -14.42% and within that year its 52-week high was 0.87 and its 52-week low was 0.33. ATNM stock is 74.69% above its 52 Week Low.
Our calculations result in a 200 day moving average of 0.55 and a 50 day moving average of 0.65. Right now, ATNM stock is trading 5.24% above its 200 day moving average.
PR Newswire: Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
Liquidity:
The company has a market cap of $67.2m with 115.7m shares outstanding and a float of 115.3m shares. Trading volume was 878,253 shares and has experienced an average volume of 1,073,386 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Actinium Pharmaceuticals Delaware was -0.41 which ended on 31st of December 2017. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.05.
Below was the last reported quarterly earnings per share:
06-30-2018: -0.04
03-31-2018: 0
12-31-2017: 0
09-30-2017: 0
Base on our calculations, the intrinsic value per share is 9.19, which means it might be undervalued and has a margin of safety of 93.68%
Indicators Also to Watch:
Based on the latest filings, there is 0.50% of insider ownership and 21.80% of institutional ownership. Short-interest was 2,974,267, which was 2.57% of shares outstanding. The short-interest ratio or days-to-cover ratio was 2.81. This stock has some short interest, but it might be normal and no need to worry if long the position.
I calculated the beta to be 1.88
PR Newswire: Bancorp 34, Inc. Announces Adoption Of Repurchase Program
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -151.13%, return on assets is -120.23% and price-to-book is 5.80.
Company Score Card:
Results are out of six:
3 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
2 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: Actinium Pharmaceuticals Delaware, ATNM, Biotechnology, Healthcare
